Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients
Launched by UNIVERSITY OF BRASILIA · Jan 6, 2009
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 65 years
- • Permanent residence in the endemic area
- • Availability of a caregiver for dependent patients
- Exclusion Criteria:
- • Mucosal disease caused by leishmaniasis
- • Disseminated cutaneous disease
- • Severe cardiac, renal or hepatic disorders
- • Active cancer
- • Active tuberculosis
- • Leprosy
- • HIV positive
- • Total bilirubin \> 1.5mg/dL
- • Urea and creatinin \> 1.5 times the upper normal level
- • Alkaline phosphatase and aminotransferases \> 2.5 times the upper normal level
- • Lipase and amylase \> 1.5 the upper normal level
- • Hemoglobin \< 5 g/dL of
About University Of Brasilia
The University of Brasília is a prestigious academic institution dedicated to advancing medical research and education. As a clinical trial sponsor, it leverages its extensive resources and expertise to facilitate innovative research initiatives aimed at improving healthcare outcomes. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring the highest standards of ethical conduct and scientific rigor in its trials. With a commitment to addressing pressing health challenges and contributing to the global body of medical knowledge, the University of Brasília plays a pivotal role in the advancement of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Corte De Pedra, Presidente Tancredo Neves, Bahia State, Brazil
Patients applied
Trial Officials
Julia S Ampuero-Vela, MD, MSc
Principal Investigator
Faculty of Medicine, University of Brasilia
Gustavo Adolfo S Romero, MD, PhD
Study Chair
Faculty of Medicine, University of Brasilia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials